1. Home
  2. BCRX
  3. BCRX News

Latest BioCryst Pharmaceuticals Inc. (BCRX) News on March 30, 2025

High Growth Tech Stocks In The US Market With Promising Potential
BCRX

Simply Wall St.

3 days ago

High Growth Tech Stocks In The US Market With Promising Potential

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%
BCRX

Simply Wall St.

12 days ago

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

24 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BCRX

MT Newswires

a month ago

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?
BCRX

Insider Monkey

a month ago

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
BCRX

Zacks

a month ago

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
BCRX

Zacks

a month ago

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
BCRX

Zacks

a month ago

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results
BCRX

Simply Wall St.

a month ago

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Company News for Feb 25, 2025
BCRX

Zacks

a month ago

Company News for Feb 25, 2025

BCRX

MT Newswires

a month ago

RBC Capital Adjusts Price Target on BioCryst Pharmaceuticals to $11 From $10, Keeps Outperform Rating

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations
BCRX

Simply Wall St.

a month ago

BioCryst Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations

BCRX

Thomson Reuters StreetEvents

a month ago

Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...
BCRX

GuruFocus.com

a month ago

BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ...

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
BCRX

Motley Fool

a month ago

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript
BCRX

Motley Fool

a month ago

BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BCRX

Zacks

a month ago

BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

BCRX

MT Newswires

a month ago

BioCryst Says Interim Data Show Orladeyo Reduced Attack Rates in Pediatric Patients With Hereditary Angioedema

BCRX

MT Newswires

a month ago

BioCryst Pharmaceuticals Q4 Adjusted Loss Narrows, Revenue Rises

BCRX

Associated Press Finance

a month ago

BioCryst: Q4 Earnings Snapshot

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
BCRX

GlobeNewswire

a month ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
BCRX

GlobeNewswire

a month ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

a month ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BCRX

Zacks

a month ago

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BCRX

MT Newswires

2 months ago

BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal

BioCryst Launches ORLADEYO® (berotralstat) in Portugal
BCRX

GlobeNewswire

2 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Exploring Three High Growth Tech Stocks In The United States
BCRX

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks In The United States

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
BCRX

GlobeNewswire

2 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
BCRX

GlobeNewswire

2 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

2 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
BCRX

Simply Wall St.

2 months ago

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock

BioCryst price target raised to $12 from $10 at Evercore ISI
BCRX

TipRanks

3 months ago

BioCryst price target raised to $12 from $10 at Evercore ISI

Exploring High Growth Tech Stocks In January 2025
BCRX

Simply Wall St.

3 months ago

Exploring High Growth Tech Stocks In January 2025

BCRX

MT Newswires

3 months ago

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
BCRX

GlobeNewswire

3 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
BCRX

GlobeNewswire

3 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

3 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%
BCRX

Simply Wall St.

3 months ago

The 4.5% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 127%

High Growth Tech Stocks To Watch In December 2024
BCRX

Simply Wall St.

4 months ago

High Growth Tech Stocks To Watch In December 2024

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

4 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future
BCRX

Simply Wall St.

4 months ago

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is Expected To Breakeven In The Near Future

BCRX

MT Newswires

4 months ago

BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator

BioCryst Launches ORLADEYO® (berotralstat) in Ireland
BCRX

GlobeNewswire

4 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Ireland

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

5 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Announces Strong Q3 2024 Revenue Growth
BCRX

TipRanks

5 months ago

BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

5 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
BCRX

Simply Wall St.

5 months ago

BioCryst Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

BCRX

Thomson Reuters StreetEvents

5 months ago

Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...
BCRX

GuruFocus.com

5 months ago

BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ...

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript
BCRX

Motley Fool

5 months ago

BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates
BCRX

Zacks

5 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates

BCRX

MT Newswires

5 months ago

BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued

BCRX

Associated Press Finance

5 months ago

BioCryst: Q3 Earnings Snapshot

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
BCRX

GlobeNewswire

5 months ago

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
BCRX

GlobeNewswire

5 months ago

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%
BCRX

Zacks

5 months ago

How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5%

High Growth Tech Stocks To Watch In October 2024
BCRX

Simply Wall St.

5 months ago

High Growth Tech Stocks To Watch In October 2024

BioCryst to Report Third Quarter 2024 Financial Results on November 4
BCRX

GlobeNewswire

5 months ago

BioCryst to Report Third Quarter 2024 Financial Results on November 4

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings
BCRX

GuruFocus.com

5 months ago

State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings

BCRX

MT Newswires

6 months ago

BioCryst Pharmaceuticals' Study of Orladeyo Finds Hospitalization Reduction for Hereditary Angioedema Patients

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
BCRX

GlobeNewswire

6 months ago

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
BCRX

Insider Monkey

6 months ago

Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
BCRX

GlobeNewswire

6 months ago

BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2
BCRX

Insider Monkey

6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2

BioCryst (BCRX) Upgraded to Buy: Here's Why
BCRX

Zacks

6 months ago

BioCryst (BCRX) Upgraded to Buy: Here's Why

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

6 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
BCRX

Zacks

6 months ago

Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?

BCRX

MT Newswires

6 months ago

BioCryst Pharmaceuticals Enrolls First Patient in Phase 1 Trial of BCX17725 to Treat Netherton Syndrome

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
BCRX

GlobeNewswire

6 months ago

BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome

BioCryst Secures Major US Health Department Influenza Drug Deal
BCRX

TipRanks

6 months ago

BioCryst Secures Major US Health Department Influenza Drug Deal

BioCryst secures $69m contract from US to supply RAPIVAB for influenza
BCRX

Pharmaceutical Technology

6 months ago

BioCryst secures $69m contract from US to supply RAPIVAB for influenza

With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns
BCRX

Simply Wall St.

6 months ago

With 80% institutional ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a favorite amongst the big guns

BCRX

MT Newswires

6 months ago

BioCryst Awarded 5-Year US Influenza Contract Worth up to $69 Million

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
BCRX

GlobeNewswire

6 months ago

U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile

BCRX

MT Newswires

6 months ago

BioCryst Pharmaceuticals Completes Negotiations with Canadian Pricing Organization for Orladeyo

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BCRX

GlobeNewswire

6 months ago

BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO® (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
BCRX

GuruFocus.com

7 months ago

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium
BCRX

GlobeNewswire

7 months ago

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Appoints Dr. Donald Fong Chief Medical Officer
BCRX

GlobeNewswire

7 months ago

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

7 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In August 2024
BCRX

Simply Wall St.

7 months ago

High Growth Tech Stocks To Watch In August 2024

BioCryst to Present at Upcoming Investor Conferences
BCRX

GlobeNewswire

7 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript
BCRX

Motley Fool

8 months ago

BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
BCRX

Zacks

8 months ago

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BCRX

Zacks

8 months ago

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

BCRX

MT Newswires

8 months ago

BioCryst Pharmaceuticals Q2 Adjusted Loss Narrows, Revenue Rises

BCRX

Associated Press Finance

8 months ago

BioCryst: Q2 Earnings Snapshot

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update
BCRX

GlobeNewswire

8 months ago

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

8 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
BCRX

Zacks

8 months ago

Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BCRX

Zacks

8 months ago

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

BioCryst to Report Second Quarter 2024 Financial Results on August 5
BCRX

GlobeNewswire

8 months ago

BioCryst to Report Second Quarter 2024 Financial Results on August 5

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
BCRX

Zacks

8 months ago

BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
BCRX

Zacks

8 months ago

Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

BioCryst Pharmaceuticals' (NASDAQ:BCRX) growing losses don't faze investors as the stock spikes 18% this past week
BCRX

Simply Wall St.

8 months ago

BioCryst Pharmaceuticals' (NASDAQ:BCRX) growing losses don't faze investors as the stock spikes 18% this past week

ORLADEYO gains approval in Peru for HAE prevention
BCRX

Pharmaceutical Technology

9 months ago

ORLADEYO gains approval in Peru for HAE prevention

BCRX

MT Newswires

9 months ago

BioCryst Pharmaceuticals Says Orladeyo Approved in Peru

ORLADEYO® (berotralstat) Approved in Peru
BCRX

GlobeNewswire

9 months ago

ORLADEYO® (berotralstat) Approved in Peru

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX

GlobeNewswire

9 months ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings
BCRX

Simply Wall St.

9 months ago

BioCryst Pharmaceuticals Insiders Added US$1.05m Of Stock To Their Holdings

Share on Social Networks: